核苷和核苷酸类药物联合聚乙二醇干扰素治疗慢性乙型肝炎的研究进展

Research progress in combination therapy with pegylated interferon and nucleos(t) ide analogues in treatment of chronic hepatitis B

聚乙二醇干扰素(PEG-IFN)与核苷和核苷酸类药物(NAs)联合应用是否能够提高慢性乙型肝炎(CHB)抗病毒的疗效,已是目前CHB抗病毒治疗的热点问题。就近年来联合治疗方面的研究成果和进展作简要概述,认为PEG-IFN初始联合NAs治疗在获得HBe Ag血清学转换或者停药后应答方面的疗效并未优于PEG-IFN单药治疗,而对PEG-IFN或NAs经治患者进行序贯或联合治疗以及联合免疫生物细胞治疗是更具应用前景的联合治疗方案。

Current antiviral treatment strategy for chronic hepatitis B （ C HB ） includes pegylated interferon （ PEG - IFN ） and nucleos （t） ide analogues （NAs）. Whether combination therapy with PEG -IFN and NAs improve therapeutic efficacy has become the key question regarding the antiviral therapy for CHB. This article reviews the recent progress in combination therapy for the management of CHB. The results indicate that the efficacy of simultaneous combination of PEG - IFN and NAs is not superior to that of PEG - IFN monotherapy in terms of HBeAg seroconversion and response after drug withdrawal. Sequential combination or switching therapy in PEG - IFN - or NAs - treated pa- tients, as well as combination with immune cell therapy, is a promising treatment strategy.